½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1449642

¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀå : Åõ¿© °æ·Îº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°

Global Blarcamesine Market, By Route of Adminsitration, By Application, By Distribution Channel, By Geography .

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀåÀº 2026³â¿¡´Â 8¾ï 2,220¸¸ ´Þ·¯°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ°í, 2026³âºÎÅÍ 2031³â±îÁö 3.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)(º¹ÇÕ ¿¬°£ ¼ºÀå·ü)À» ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2031³â¿¡´Â 9¾ï 9,240¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2023³â 2023³â ¹× 2024³â ½ÃÀå ±Ô¸ð 8¾ï 2,220¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2026-2031³â
¿¹Ãø±â°£ 2023³â ¹× 2024³â-2030³â ¹× 2031³â CAGR : 3.80% 2030³â ¹× 2031³â °¡Ä¡ ¿¹Ãø 9¾ï 9,240¸¸ ´Þ·¯
±×¸² 1. ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å Áö¿ªº° ½ÃÀå Á¡À¯À²(%)(2026³â)
Global Blarcamesine Market-IMG1

ºí¶óÄ«¸Þ½ÅÀº ¼¼Æ÷³» ½Ã±×¸¶-1 »þÆä·Ð ´Ü¹éÁúÀÇ ÀÛ¿ëÁ¦ÀÔ´Ï´Ù. ±¸Ã¼ÀûÀ¸·Î´Â ½Ã±×¸¶ 1/¹«½ºÄ«¸° ¼ö¿ëüÀÇ È¥ÇÕ ¸®°£µåÀÔ´Ï´Ù. ´ëºÎºÐÀÇ Á¶Á÷¿¡¼­ ¹ßÇöµÇ°í ¹ÌÅäÄܵ帮¾Æ¿Í ¼ÒÆ÷ü »çÀÌÀÇ ±¹¼Ò Á¢Á¡¿¡ À§Ä¡ÇÏ´Â ½Ã±×¸¶ 1 ¼ö¿ëü´Â ¸¹Àº ´Ù¸¥ ¸· ¼ö¿ëü¿Í ÀÌÁ¾ÀÌ·®Ã¼¸¦ Çü¼ºÇÏ¿© ´ÙÁß ¼¼Æ÷ °æ·Î ±×¸®°í »ý¸®Àû °úÁ¤¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ºí¶óÄ«¸Þ½ÅÀº ½Ã±×¸¶-1 ¼ö¿ëü¿¡´Â ³ôÀº ³ª³ë¸ô, ¹«½ºÄ«¸° ¼ö¿ëü¿¡´Â ³·Àº ¸¶ÀÌÅ©·Î¸ô ¹üÀ§¿¡¼­ °áÇÕÇÏ´Â °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. ÀÌ È­ÇÕ¹°Àº ¹«½ºÄ«¸° ¼ö¿ëü ±æÇ×Á¦ÀÇ ½ºÄÚÆ÷¶ó¹Î, ÇÕ¼º AB ¿Ã¸®°í¸Ó ÁÖ»ç, NMDA ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ µðÁ¶½ÇÇÉÀ¸·Î ó¸®ÇÑ ¸¶¿ì½º¿¡¼­ ±â¾ï À¯Áö ÀÛ¿ë°ú ½Å°æ º¸È£ ÀÛ¿ëÀ» ³ªÅ¸³»´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ½À´Ï´Ù(Villard et al.). AB ¿Ã¸®°í¸Ó ÁÖ»ç ¸ðµ¨À» ÀÌ¿ëÇÑ ´Ù¸¥ ¿¬±¸´Â ºí¶óÄ«¸Þ½ÅÀÌ Å¸¿ìÀÇ °úµµÇÑ ÀλêÈ­¸¦ ¾ïÁ¦ÇÏ°í ¹ÌÅäÄܵ帮¾Æ¸¦ º¸È£ÇÒ °¡´É¼ºÀ» ½Ã»çÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

Á¤ºÎ Àΰ¡ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 12¿ù 19ÀÏ, ½Å°æÅðÇ༺ Áúȯ ¹× ½Å°æ¹ß´Þ Àå¾ÖÀÇ Ä¡·á¸¦ À§ÇÑ Â÷º°È­µÈ Ä¡·áÁ¦¸¦ °³¹ßÇÏ´Â ÀÓ»ó ´Ü°èÀÇ ¹ÙÀÌ¿ÀÀǾàÇ° ±â¾÷ÀÎ ¾Æ³ªº¤½º »ý¸í°úÇлç´Â À¯·´ÀǾàû(EMA)ÀÇ Àΰ£¿ë ÀǾàÇ° À§¿øȸ(CHMP)°¡ ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ´ëÇÑ °æ±¸ ºí¶óÄ«¸Þ½ÅÀÌ À¯·´ ÀǾàûÀÇ ÁýÁßÈ­µÈ ÀýÂ÷¿¡ µû¶ó EU¿¡¼­ ÆǸŠ½ÂÀÎ ½ÅûÀ» Á¦ÃâÇÒ ÀÚ°ÝÀÌ ÀÖÀ½¿¡ ÇÕÀÇÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Ư¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2023³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2026-2031³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ºí¶óÄ«¸Þ½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆà ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆà Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀåÀ» ºÐ¼®Çϴµ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÃÖ±Ù µ¿Çâ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´, Àμö ¹× Çù¾÷

Á¦4Àå ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀå-Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø ¹× ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ºí¶óÄ«¸Þ½Å ½ÃÀå : Åõ¿© °æ·Îº°(2019-2031³â)

  • °æ±¸
  • ºñ°æ±¸

Á¦6Àå ¼¼°èÀÇ ºí·¢ Ä«¸Þ½Å ½ÃÀå :¿ëµµº°(2019-2031³â)

  • ¾ËÃ÷ÇÏÀ̸Ӻ´
  • ÆÄŲ½¼º´
  • Ä¡¸Å
  • ·¿ ÁõÈıº
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ºí·¢ Ä«¸Þ½Å ½ÃÀå : À¯Åë ä³Îº°(2019-2031³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ ºí·¢ Ä«¸Þ½Å ½ÃÀå : Áö¿ªº°(2019-2031³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîƼ³ª
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Anavex Life Sciences

Á¦10Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆǻ翡 ´ëÇØ
AJY 24.04.02

Global blarcamesin market will be valued at US$ 822.2 Mn in 2026 and is expected to reach US$ 992.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.8% from 2026 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 822.2 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2026 to 2031.
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.80% 2030/2031 Value Projection: US$ 992.4 Mn
Figure 1. Global Blarcamesine Market Share (%), By Region, 2026
Global Blarcamesine Market - IMG1

Blarcamesine is an agonist of the intracellular sigma-1 chaperone protein. Specifically, it is a mixed ligand for sigma1/muscarinic receptors. Expressed in most tissues and located at focal contacts between mitochondria and the endoplasmic reticulum, the sigma-1 receptor forms heterodimers with many other membrane receptors and, as such, influences multiple cellular pathways and physiological processes. Blarcamesine reportedly binds the sigma-1 receptor in the high nanomolar and the muscarinic receptor in the low micromolar range. The compound has been reported to have memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic AB oligomer injection, or with the NMDA receptor agonist dizocilpine (Villard et al., 2011). Other studies in the AB oligomer injection model suggest that blarcamesine may block tau hyperphosphorylation and protect mitochondria.

Market Dynamics:

Increasing government approval is expected to drive the growth of the market over the forecast period. For instance, on December 19, 2023, Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer's disease is eligible for submission of an application for a Union Marketing Authorization in the EU under the European Medicines Agency's centralized procedure.

Key features of the study:

  • This report provides in-depth analysis of the global blarcamesine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global blarcamesine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Anavex Life Sciences
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global blarcamesine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blarcamesine market

Detailed Segmentation:

  • Global Blarcamesine Market, By Route of Administration
    • Oral
    • Parentral
  • Global Blarcamesine Market, By Application
    • Alzheimer's Disease
    • Parkinson's Disease
    • Dementia
    • Rett Syndrome
    • Others
  • Global Blarcamesine Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Blarcamesine Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Blarcamesine Market:
    • Anavex Life Sciences

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Blarcamesine Market, By Route of Administration
    • Global Blarcamesine Market, By Application
    • Global Blarcamesine Market, By Distribution Channel
    • Global Blarcamesine Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing research and development activities
    • Strict regulatory requirements
    • Emerging markets
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Blarcamesine Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Blarcamesine Market, By Route of Administration, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Blarcamesine Market, By Application, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Alzheimer's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Parkinson's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Dementia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Rett Syndrome
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Blarcamesine Market, By , 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Blarcamesine Market, By Region, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031(%)
    • Y-o-Y Growth Analysis, For Region,
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profile
    • Anavex Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦